TABLE 2.
Clinical and biochemical measurements across quartiles (Q) of plasma pyridoxal 5′-phosphate (PLP)1
| PLP |
|||||
| Pearson correlation (r) | Q1 (5.5–28.3 nmol/L) | Q2 (28.4–42.4 nmol/L) | Q3 (42.5–65.2 nmol/L) | Q4 (65.3–737 nmol/L) | |
| n | — | 292 | 290 | 299 | 295 |
| Glucose (mg/dL) | −0.102 | 137 ± 43 | 120 ± 3 | 119 ± 3 | 113 ± 3 |
| Hb Alc (%) | −0.084 | 7.5 ± 0.1 | 7.0 ± 0.1 | 6.9 ± 0.1 | 6.8 ± 0.1 |
| Insulin (uIU/mL) | 0.010 | 21.0 ± 1.7 | 18.2 ± 1.2 | 17.0 ± 0.9 | 16.4 ± 0.9 |
| HOMA-IR | −0.03 | 8.8 ± 1.7 | 6.0 ± 0.6 | 5.5 ± 0.5 | 4.7 ± 0.3 |
| HOMA–β cell function | 0.084 | 141 ± 11 | 158 ± 12 | 153 ± 17 | 166 ± 16 |
| Triglycerides (mg/dL) | 0.02 | 156 ± 6 | 159 ± 7 | 172 ± 9 | 168 ± 6 |
| Total cholesterol (mg/dL) | 0.01 | 177 ± 2 | 185 ± 2 | 186 ± 2 | 187 ± 3 |
| LDL-C (mg/dL) | −0.01 | 103 ± 2 | 109 ± 2 | 109 ± 2 | 108 ± 2 |
| HDL-C (mg/dL) | 0.065 | 43.0 ± 0.7 | 44.4 ± 0.6 | 45.6 ± 0.7 | 46.6 ± 0.8 |
| Homocysteine (μm/L) | −0.112 | 9.9 ± 0.3 | 9.5 ± 0.3 | 8.9 ± 0.3 | 8.3 ± 0.2 |
| Diastolic BP (mm Hg) | −0.04 | 81.2 ± 0.6 | 81.7 ± 0.6 | 81.0 ± 0.6 | 80.0 ± 0.6 |
| Systolic BP (mm Hg) | −0.02 | 137 ± 1.2 | 135 ± 1 | 136 ± 1 | 136 ± 1 |
1
Hb Alc, glycated hemoglobin; HOMA-IR, homeostasis model assessment of insulin resistance; HOMA–β cell function, homeostasis model assessment of β cell function; LDL-C, LDL cholesterol; HDL-C, HDL cholesterol; BP, blood pressure. Partial Pearson's correlation coefficient was adjusted for age, sex, BMI, smoking status, alcohol intake, physical activity, and intake of dietary vitamin B-6 and total energy.
2
P < 0.001.
3
Mean ± SEM (all such values).
4
P < 0.01.
5
P < 0.05.